Strategic Objectives

• Deepen the study of the pathophysiological mechanisms of MS in order to identify new therapeutic targets for the disease and contribute to the personalized treatment of patients.
• Study the mechanisms associated with progressive forms of the disease, for which there is only one currently approved treatment.
• Identify immunological factors that early predict the risk of progression in MS in order to establish personalized therapy for this disease.
• Evaluate biomarkers of response to treatment and identify patients at risk of serious side effects.
• Study environmental factors that play a role in the course of the disease, to see if modifying them could have a beneficial effect on patients.

Research Lines

• Search for biomarkers that identify the best benefit/risk profile for different biologic therapies in MS.
• Search for biomarkers to identify the risk of progression in MS.
• Immunological mechanisms that are associated with primarily progressive forms of MS.
• Association of antibodies to Epstein-Barr virus and clinical and immunologic phenotype in MS.
• Study of the response to vaccines against SARS-CoV-2 in MS.
• Study of pathological mechanisms in MS.